These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 37894903)

  • 21. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-bonded force field model with advanced restrained electrostatic potential charges (RESP2).
    Schauperl M; Nerenberg PS; Jang H; Wang LP; Bayly CI; Mobley DL; Gilson MK
    Commun Chem; 2020; 3():. PubMed ID: 34136662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
    Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
    Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
    Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
    Degirmenci U; Wang M; Hu J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics.
    Fusani L; Palmer DS; Somers DO; Wall ID
    J Chem Inf Model; 2020 Mar; 60(3):1528-1539. PubMed ID: 31910338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution.
    Tian C; Kasavajhala K; Belfon KAA; Raguette L; Huang H; Migues AN; Bickel J; Wang Y; Pincay J; Wu Q; Simmerling C
    J Chem Theory Comput; 2020 Jan; 16(1):528-552. PubMed ID: 31714766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covalent Inhibition in Drug Discovery.
    Ghosh AK; Samanta I; Mondal A; Liu WR
    ChemMedChem; 2019 May; 14(9):889-906. PubMed ID: 30816012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells.
    Chen D; Si W; Shen J; Du C; Lou W; Bao C; Zheng H; Pan J; Zhong G; Xu L; Fu P; Fan W
    Cell Death Dis; 2018 Feb; 9(2):188. PubMed ID: 29416005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
    Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
    Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
    Liu S; Zha J; Lei M
    Clin Transl Oncol; 2018 Mar; 20(3):374-381. PubMed ID: 28766096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.
    Brenan L; Andreev A; Cohen O; Pantel S; Kamburov A; Cacchiarelli D; Persky NS; Zhu C; Bagul M; Goetz EM; Burgin AB; Garraway LA; Getz G; Mikkelsen TS; Piccioni F; Root DE; Johannessen CM
    Cell Rep; 2016 Oct; 17(4):1171-1183. PubMed ID: 27760319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
    Blake JF; Burkard M; Chan J; Chen H; Chou KJ; Diaz D; Dudley DA; Gaudino JJ; Gould SE; Grina J; Hunsaker T; Liu L; Martinson M; Moreno D; Mueller L; Orr C; Pacheco P; Qin A; Rasor K; Ren L; Robarge K; Shahidi-Latham S; Stults J; Sullivan F; Wang W; Yin J; Zhou A; Belvin M; Merchant M; Moffat J; Schwarz JB
    J Med Chem; 2016 Jun; 59(12):5650-60. PubMed ID: 27227380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations.
    Miller BR; McGee TD; Swails JM; Homeyer N; Gohlke H; Roitberg AE
    J Chem Theory Comput; 2012 Sep; 8(9):3314-21. PubMed ID: 26605738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Covalent docking using autodock: Two-point attractor and flexible side chain methods.
    Bianco G; Forli S; Goodsell DS; Olson AJ
    Protein Sci; 2016 Jan; 25(1):295-301. PubMed ID: 26103917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ONIOM Method and Its Applications.
    Chung LW; Sameera WM; Ramozzi R; Page AJ; Hatanaka M; Petrova GP; Harris TV; Li X; Ke Z; Liu F; Li HB; Ding L; Morokuma K
    Chem Rev; 2015 Jun; 115(12):5678-796. PubMed ID: 25853797
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.